The induction of antigen-specific CTL by *in situ* Ad-REIC gene therapy

Yuichi Ariyoshi¹, Masami Watanabe¹, Shingo Eikawa², Chihiro Yamazaki², Takuya Sadahira¹, Takeshi Hirata¹, Motoo Araki¹, Shin Ebara¹, Yasutomo Nasu¹, Heiichiro Udono², Hiromi Kumon¹

1) Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

2-5-1 Shikata-cho, Okayama, 700-8558, JAPAN.
Tel: +81-86-235-7287
Fax: +81-86-231-3986

Corresponding author is Yasutomo Nasu.
E-mail: ynasu@md.okayama-u.ac.jp

This work was supported by JSPH KAKENHI Grant Numbers 15H04974, 15H04297, 26462413.

Okayama University and Momotaro-Gene Inc. are applying for patents on the Ad-REIC systems.
Drs. M. Watanabe, Y. Nasu and H. Kumon are the inventors of the patents and own stock in
Momotaro-Gene Inc.

The final word count, excluding references and figure text is 3964 words.
Abstract

An adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) mediates simultaneous induction of cancer-selective apoptosis and augmentation of anti-cancer immunity. In our preclinical and clinical studies, in situ Ad-REIC gene therapy showed remarkable direct and indirect anti-tumor effects to realize therapeutic cancer vaccines. We herein aimed to confirm the induction of tumor-associated antigen specific cytotoxic T-lymphocytes (CTLs) by Ad-REIC. Using an OVA, a tumor associated antigen (TAA), expressing E.G7 tumor-bearing mouse model, we investigated the induction and expansion of OVA-specific CTLs responsible for indirect, systemic effects of Ad-REIC. The intratumoral administration of Ad-REIC mediated clear anti-tumor effects with the accumulation of OVA-specific CTLs in the tumor tissues and spleen. The CD86-positive dendritic cells (DCs) were up-regulated in the tumor draining lymph nodes of Ad-REIC treated mice. In a dual tumor-bearing mouse model in the left and right back, Ad-REIC injection in one side significantly suppressed the tumor growth on both sides and significant infiltration of OVA-specific CTLs into non-injected tumor was also detected. Consequently, in situ Ad-REIC gene therapy is expected to realize a new generation cancer vaccine via anti-cancer immune activation with DC and tumor antigen-specific CTL expansion.
Introduction

The Reduced Expression in Immortalized Cells (REIC) gene is a member of the DKK family genes (hDKK-1,2,3 and 4) with homology to Xenopus laevis Dickkopf gene. REIC/Dkk-3 was originally isolated as an immortalization related gene of normal human fibroblasts and was regarded as a tumor suppressor gene (1, 2). The expression of the REIC/Dkk-3 gene is significantly reduced in a wide range of cancer cells (3-6). Although Dkk-3 does not bind with LDL-receptor-related protein 5/6 (LRP5/6) and the precise mechanism by which Dkk-3 interferes with Wnt signaling remains an obstacle (7-9), its biological functions in the embryonic development (10, 11) and emerging roles in cancer therapy (2) have been studied with increasing attention. In addition, our previous study showed that REIC/Dkk-3 protein has a cytokine-like effects, responsible for the differentiation of human CD14+monocyte into a novel cell type, dendritic cell (DC)-like cell (12, 13).

An adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) allowed the forced expression of REIC/Dkk-3, and induced apoptosis in a variety of cancer cells in vitro and in vivo (14-18). The molecular mechanisms of these apoptotic events have been proved to be induced by unfolded protein response in the endoplasmic reticulum (ER stress) with c-Jun N-terminal kinase (JNK) activation (19-21). Interestingly, ER stress mediates the enhanced IL-7 expression in co-infected normal fibroblasts, resulting in the activation of innate immunity involving natural killer (NK) cells (22). Furthermore, the secreted REIC protein with immunomodulatory function creates an optimal environment for the activation of host immune cells, inducing cytotoxic T lymphocytes (12, 13, 23).

In the present study, we focus on the antigen-specific CTL responses mediated by in situ Ad-REIC gene therapy. Using a model of a tumor cell line carrying specific antigen, ovalbumin (OVA), we investigated in vivo antitumor effects via OVA specific immune response generated by Ad-REIC gene therapy.
Results

**REIC/Dkk-3 induced apoptosis in E.G7 cell lines**

The specific induction of apoptosis was demonstrated in E.G7 cells by Ad-REIC treatment. We first assessed the *in vitro* apoptotic effects of Ad-REIC in comparison to control vector, Ad-LacZ. E.G7 cells were infected with Ad-LacZ or Ad-REIC at 100 MOI and 500 MOI. We monitored apoptotic cells at 48 h after infection by Hoechst staining. The Ad-REIC vector significantly enhanced the *in vitro* apoptosis induction in comparison to the control vectors transfected at 500 MOI. (Figure 1a and 1b) At 500 MOI, 41.2 ± 8.64 % of Ad-REIC-infected E.G7 cells were positive for Hoechst staining; in contrast, only 18.4 ± 4.16 % of Ad-LacZ cells were positive (P<0.01).

**In vivo Ad-REIC gene therapy suppressed the growth of E.G7 tumors**

We used an E.G7 mouse model to reveal the direct antitumor effects of Ad-REIC gene therapy (Figure 2a). We first evaluated the levels of REIC/Dkk-3 protein expression in E.G7 tumors. The overexpression of REIC/Dkk-3 was observed after the intratumoral injection of Ad-REIC in E.G7 tumors; this response was not observed in control settings (Figure 2b). We next investigated whether Ad-REIC inhibits tumor growth *in vivo*. The significant suppression of tumor growth was observed from day 10 in the Ad-REIC treated group in comparison to the Ad-LacZ group (P < 0.01) (Figure 2c).

**Tumor antigen-specific CTLs were induced by Ad-REIC gene therapy**

We examined whether tumor antigen-specific CTLs could be induced by Ad-REIC gene therapy. E.G7 tumor bearing mice were intratumorally injected with Ad-REIC or Ad-LacZ. Two days after the injection, the mice were sacrificed and examined to determine whether OVA-specific CTLs had accumulated in the tumor-infiltrating lymphocytes (TILs). OVA-specific CTLs were detected by OVA tetramer composing MHC H-2 Kb + OVA 257-264.
As shown in Figure 3a, a higher percentage of OVA tetramer + CD8 + T cells was detected in the Ad-REIC treated TILs in comparison to the control vector injected mice (18.8 % vs. 3.4 %, respectively; P = 0.02). We next evaluated the systemic immune response. After injection of the vector, the spleen was harvested and single cell suspensions were prepared. Splenetic cells were cultured with OVA peptide for 7 days. After ex vivo OVA peptide stimulation, OVA-specific CTLs were detected by OVA tetramer. OVA tetramer+ cells were significantly higher in the Ad-REIC treated spleen in comparison to the control mice (24.2 % vs. 1.1 %, respectively; P = 0.04) (Figure 3b). These results showed that Ad-REIC gene therapy significantly induced OVA-specific CTL responses in both the TILs and the lymphoid organs (Figure 3c).

Induced CTL produce IFN-γ.

To evaluate the production ability of IFN-γ, CD8+ TILs and the tumor draining lymph nodes (TDLNs) were cultured with PMA/ionomycin for 4 h. PMA was a useful tool for monitoring the capacity for cytokine production of CD8+ T cells (24). IFN-γ producing cells were not observed in Ad-LacZ treated TILs and TDLN. The CTLs from Ad-REIC treated mice produced large amounts of IFN-γ after PMA/ionomycin stimulation (Figure 4a, b). As compared to Ad-LacZ, Ad-REIC gene therapy strongly induced IFN-γ production in CD8+ TILs and the TDLNs (TILs: 0.07 ± 0.11 % vs. 2.27 ± 0.63 %, respectively; P = 0.02; TDLN: 0.18 ± 0.07 % vs. 2.34 ± 0.58 %, respectively; P = 0.02) (Figure 4c).

Characterization of dendritic cells in the tumor draining lymph node

To investigate the dendritic cell (DC) subsets after Ad-REIC treatment, TDLNs were removed and analyzed by flow cytometry. In the TDLNs, there were two subsets: CD11c int MHC class II high subset (mDC) and CD11c high MHC class II int subset (rDC) (25). In the Ad-REIC injection mice, more than 1.0 x 10^4 cells were mDCs and about 7.0 x 10^3 cells were rDCs. On the other hand, the numbers of cells in both DC subsets were <5.0 x 10^3 in Ad-LacZ treated mice (Figure
5a). CD103 (+) mDC and CD8 (+) rDC are known to have the ability of cross-presentation (26-28). Significant amount of induced DCs in Ad-REIC injected mice were found to be subset with ability of cross-presentation (Figure 5b). More importantly, in Ad-REIC injected TDLNs, both DC subsets showed higher expression levels of CD86, which is used as an activation marker, in comparison to Ad-LacZ mice (Figure 5c).

The systemic antitumor effect could be induced by in-situ Ad-REIC gene therapy

In order to assess anti-tumor effects of Ad-REIC gene therapy on distant tumors, we developed a dual tumor-bearing mouse model (Figure 6a). E.G7 cells were injected into the left and right back of a mouse. When the tumor diameter reached 5mm, Ad-REIC was injected into the right side of the tumor only. Forty-eight hours after the second injection, the TILs were examined to detect OVA-specific CTLs. At 1 week after the second injection, complete tumor growth suppression was observed in the Ad-REIC treated group, though the dual tumor grew in the Ad-LacZ treated mice (Figure 6a). To evaluate the indirect immune response, TILs were harvested from the non-injection side. As shown in Figure 6b, a significant number of OVA-specific CD8+ T cells were detected in non-injected tumor of Ad-REIC treated mice as compared to control Ad-LacZ treated mice (11 % vs. 0.65 %, respectively; P < 0.01) (Figure 6b). In this dual tumor-bearing mouse model, it was confirmed that OVA-specific CTLs derived from Ad-REIC injected tumor were responsible for anti-tumor effects on non-injected tumor. Using this model and anti-CD8 antibody to deplete the T cell functions, we also confirmed that the anti-tumor effects were dependent on the CD8+ T lymphocyte, including the CTLs (Figure 6c, d). We also examine anti-tumor effects in the other dual tumor-bearing mouse model of prostate cancer. Using human prostate specific antigen (PSA)-expressing RM9 cancer cells, we further demonstrated the anti-tumor effects in the dual tumor (Figure 6e).
Discussion

The new strategy, based on the concept of simultaneous induction of selective killing of cancer cells and augmentation of antitumor immunity, leads to a new generation of cancer vaccines and it is expected to become a leading standard in the treatment of most solid cancers with gene therapy. To realize this concept, oncolytic viruses armed with GM-CSF, such as T-VEC (talimogene laherparepvec, an oncolytic herpes simplex type I virus) and Pexa-Vec (pexastimogene devacirepvec; an oncolytic vaccinia poxvirus) have already been successfully developed (29-31). Similarly, we are now developing Ad-REIC as a new therapeutic cancer vaccine using an original multifunctional therapeutic gene of REIC/Dkk-3.

In our preclinical and clinical studies on \textit{in situ} gene therapy, indirect, systemic anti-tumor effects induced by Ad-REIC were found to be strong enough to be realized as therapeutic cancer vaccines. For instance, in an orthotopic prostate cancer model with pre-established lung metastases using RM-9 mouse prostate cancer cells, intraprostatic injection of Ad-REIC significantly suppressed the local tumor growth and pre-established lung metastases, leading to a prolonged mice survival (12, 32). The First-In-Man clinical study, a phase I/Iia study of \textit{in situ} Ad-REIC gene therapy for prostate cancer (PCa), was initiated at Okayama University in January 2011(33). Two groups of patients were treated at 4 escalating doses: group A consisting of patients with castration-resistant PCa (CRPC) with or without metastasis, and group B consisting of patients with high-risk, localized PCa scheduled to undergo radical prostatectomy. As of November 2014, 8 patients in group A and 18 scheduled patients in group B were treated, demonstrating remarkable safety profiles of Ad-REIC. These clinical data with dose-dependent decrease in PSA (a tumor marker), immuno-pathological effects in surgical specimens and favorable outcomes in biochemical recurrence-free survival after radical prostatectomy in group B will be published elsewhere. In group A, dramatic systemic effects induced by \textit{in situ} gene therapy were illustrated in a case of chemotherapy resistant advanced CRPC with bulky lymph node metastasis (33). According to these preclinical and clinical results, we propose that the
mechanism of action of in situ Ad-REIC is as follows: intratumoral injection of Ad-REIC induces massive apoptosis of cancer cells due to ER stress and provides an ideal presentation of possible cancer antigens to the host immune system. Secreted REIC protein at the tumor site creates an optimal environment, mediating tumor-associated, antigen-specific cytotoxic T cells. In addition, the overproduction of IL-7 by cancer-associated fibroblasts activates innate immunity involving NK cells (22, 33).

Since the induction of activated DCs and antigen-specific CTLs is crucial for the development of therapeutic cancer vaccines by Ad-REIC, we investigated this process carefully in a mouse tumor model using E.G7 expressing OVA. The expression of REIC/Dkk-3 is lost in E.G7 tumors. In vitro susceptibility of E.G7 to Ad-REIC was low and a high MOI (500 MOI) was needed to induce sufficient apoptosis in the in vitro study (Figure 1). Nevertheless, remarkable in vivo killing effects by Ad-REIC on subcutaneous E.G7 tumor were obtained (Figure 2).

In general, naive CD8+ T cells interact with TAA-loaded APCs and acquire an effector function (34). In this murine model, cell-associated OVA might be internalized by DCs in the treatment process of Ad-REIC and OVA peptide with the major histocompatibility complex (MHC) class I was presented to naïve CD8+ T cells. The resulting OVA-specific CTLs were detected successfully by a peptide-MHC tetramer assay, which is the most reliable assay for investigating antigen-specific CTL (Figure 3). In addition, CD8+ T cells, including OVA-tetramer+ cells, showed IFN-γ production capacity, which is a functional surrogate marker for identifying peptide-specific CTL activity.

As cross-presentation is a critical step for the priming of effective anti-cancer T cell responses, we performed an in vitro cross-presentation assay using OT-1 cells as indicated in our previous study (35, 36). Unexpectedly, OT-1 cells showed poor IFN-γ production after co-culture with DCs from Ad-REIC treated mice (data not shown). Nevertheless, DCs were CD8+ rDCs and CD103+ mDCs phenotype, whose expression levels of CD86 were higher than those of DCs from control Ad-LacZ treated mice (Figure 5). CD86 is an activated marker and both CD8+...
rDCs and CD103+ mDCs are known to have cross-presentation ability (37). Therefore, it is highly plausible that Ad-REIC gene therapy influences the cross-presentation pathway in DCs. In our previous study, recombinant REIC/Dkk-3 protein with cytokine-like function was shown to induce the differentiation of human CD14+ monocytes into a novel cell type, DC-like cells (12). The intratumoral administration of REIC/Dkk-3 protein significantly suppressed subcutaneous RM9 tumor growth with CD11c+ and CD8+ (dendritic and killer T cell marker, respectively) cell accumulation as determined by an immunohistochemical analysis (12). Furthermore, a 17 kDa cysteine-rich core domain was recently shown to be sufficient for the induction of DC-like cell differentiation from monocytes (13). Concomitant with the differentiation of DCs, the REIC/Dkk-3 protein induced the phosphorylation of glycogen synthase kinase 3β (GSK-3β) and signal transducers and activators of transcription (STAT) 3 and STAT5 at a level comparable to that of GM-CSF (13). According to these observations, it is possible that REIC/Dkk-3 protein secreted from tumors influences DC activation and differentiation.

Consequently, activated DCs in the TDLNs sufficiently induced OVA-specific CTLs, which circulated throughout the body and infiltrated into non-injected tumor in the present dual tumor-bearing murine model (Figure 6). In this process, CD8+ CTLs play and essential roles in the anti-tumor effects based on the results with anti-CD8 antibody to deplete the T cell functions. Using mouse prostate cancer model with human PSA-expressing tumor, we further confirmed the generalizability of the current experiments in the other tumor type of prostate cancer. Challenges for the routine detection of antigen-specific CTLs induced by Ad-REIC have not been successful in our phase I/IIa clinical trial in prostate cancer. However, the present findings on OVA-specific CTLs induced by Ad-REIC in the E.G7 mouse model and on PSA-expressing tumor mouse model are extremely helpful to support our promising clinical results obtained and proposed action mechanism of in situ Ad-REIC to generate personalized therapeutic cancer vaccines.
Materials and methods

Mice and cell lines

C57BL/6 female mice (ages: 6-8 weeks), were obtained from CLEA Japan. All mice were maintained under specific pathogen-free conditions in Okayama University. E.G7 is an OVA cDNA transfected derivative of the EL4 (methylcholanthrene-induced thymoma of C57BL/6 [H-2b] origin) cell line. The E.G7 cells were kindly provided by Prof. Udono. The E.G7 cells were maintained with RPMI-1640 containing 10% FCS, 2 mM l-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid, penicillin-streptomycin, 2-mercaptoethanol and 400 μg/ml G418.

Adenovirus vector carrying REIC/Dkk-3

To induce the overexpression of REIC/Dkk-3, an adenovirus vector carrying the REIC/Dkk-3 gene (Ad-REIC) was created. A full-length cDNA was integrated into a cosmid vector pAxCAwt and transferred into an adenovirus vector using the COS-TPC method (Takara Bio, Shiga, Japan). An adenovirus vector carrying the LacZ gene (Ad-LacZ) was used as a control.

Apoptosis assay

E.G7 cells (1.0 x 10^5 cells) were seeded in 6-well plates and incubated in culture medium for 24 h. The cells were then treated with Ad-LacZ or Ad-REIC at the indicated MOI in 2 ml of medium. After 24 h of incubation, the apoptotic cells were visualized by Hoechst 33342 staining, and the apoptotic rate was analyzed as previously described (38, 39).

Western blot analysis

Total protein was extracted from the treated tumor tissue and Western blotting was performed as described previously (14). Proteins were identified with the use of the mouse monoclonal anti-human REIC/Dkk-3 antibody, which was raised in our laboratory, at 1000 x dilution.
**In vivo experiments**

E.G7 cells were suspended in serum-free medium and inoculated intradermally into the left back of mice (1 x 10^6 cells in 200 μl). One week after injection, when the tumor reached ~10 mm in diameter, Ad-REIC or Ad-LacZ was injected intratumorally at a dose of 1 x 10^9 pfu in (40)100 μL of PBS. Mice received a 2nd injection of Ad-REIC or Ad-LacZ 2 days after the 1st injection. The size of the tumors was measured every 2 days. The tumor volume was calculated using an empirical formula, \( V = \frac{1}{2} \times (\text{the shortest diameter}) \times (\text{the shortest diameter}) \times (\text{the longest diameter}) \). The experiments were performed according to the guidelines of Okayama University. In the CD8-depleting experiments, mice were anesthetized with ether, after which anti-Lyt-2.2 (CD8) antibody diluted in PBS to a total dose of 200 μL per mouse was injected intraperitoneally (24). In the other experiments, mouse prostate cancer cell line, PSA-RM9, which is stably transfected and expresses human prostate specific antigen (PSA), was used as previously described (40).

**Flow cytometric analysis**

The following fluorochrome-labeled anti-mouse mAbs were used. PerCP/Cy5.5 conjugated anti-mouse CD19 (BioLegend), PE-Cy7 conjugated anti-mouse CD8α(BioLegend), APC-Cy7 conjugated anti-mouse CD11c (BioLegend), FITC conjugated anti-mouse MHC Class II (I-A/I-E) (eBioscience), PE conjugated anti-mouse CD11b (BioLegend), APC conjugated anti-mouse CD103 (BioLegend) and PE conjugated anti-mouse CD86 (BioLegend) were used for detection of DC populations. Cells were washed and incubated with mAbs for 30min at 4 °C in 5 mM EDTA and PBS containing 2 % FCS (FACS buffer). All stained cells were acquired on a FACSCanto with the FACSDiva software program (BD Biosciences, Palo Alto, CA, USA) and analyzed using the FlowJo software program (TreeStar, San Carlos, CA).
Tetramer assays

For the analysis of OVA-specific CTL frequency, lymphocytes were obtained from the spleen and TDLNs and TILs on day 2 after the last treatment. The TIL and TDLN cells were washed twice in FACS buffer and incubated with PE-conjugated H-2Kb OVA tetramer (MBL) for 30 min at RT. After tetramer staining, PE-Cy7 conjugated anti-mouse CD4 (BioLegend) and APC-Cy7 conjugated anti-mouse CD8α (BioLegend) were used for cell surface staining. After harvesting the splenocytes from the mice on the indicated days, the cells were co-incubated with OVA257–264 peptide (SIINFEKL) for 5 days. The incubated cells were also stained by OVA tetramer and cell surface Ab. The frequency of OVA-specific CD8+ cells were analyzed on a FACSCanto II system.

Intracellular cytokine assay

For the DLN and naive T cell intracellular cytokine staining, samples were restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h. The cells were surface stained with APC-Cy7 conjugated anti-mouse CD8α (BioLegend). The cells were washed, fixed and permeabilized with Cytofix/Cytoperm buffer and intracellular staining was performed with PE conjugated anti-mouse IFN-γ (eBioscience). Finally, The cells were analyzed with a FACSCanto II system.

Statistical analysis

All data expressed as the means ± s.e.m. and representative of at least two different experiments. The statistical differences between the groups were assessed by analyzing means of replicates using the two-tailed Student’s t test. A P value of <0.05 indicated that the value of the test sample was significantly different from that of the relevant controls.
Acknowledgements

This work was supported by JSPH KAKENHI Grant Numbers 15H04974, 15H04297, 26462413.

Conflict of Interest

Okayama University and Momotaro-Gene Inc. are applying for patents on the Ad-REIC systems. Drs. M. Watanabe, Y. Nasu and H. Kumon are the inventors of the patents and own stock in Momotaro-Gene Inc.
Figure legends

Figure 1. The induction of apoptosis in E.G7 tumor cells after infection with Ad-REIC
(a) Hoechst staining of Ad-REIC or Ad-LacZ treated E.G7 cells. E.G7 cells were infected with Ad-LacZ or Ad-REIC at 100 MOI and 500 MOI. Apoptotic cell death was examined in terms of changes in cell morphology which were observed by Hoechst 33342 staining.
(b) The quantitation of the apoptotic cells is shown. Vertical bars, standard deviation. The P value was calculated using the paired t-test.

Figure 2. The antitumor effect of in situ Ad-REIC gene therapy
(a) The experimental schedule of the Ad-REIC treatment is shown. After the tumor volume reached 5mm, 1 x 10^9 pfu of Ad-REIC or Ad-LacZ was intoratumorally injected two times.
(b) A Western blot analysis of the expression of REIC/Dkk-3 protein in E.G7 tumors after injection. Tubulin was used as a loading control.
(c) The growth curve of the E.G7 tumors. The tumor size was monitored 2 weeks after Ad-REIC or Ad-LacZ treatment into E.G7 bearing mice. The tumor volume was measured as described in the Materials and Methods section. A significant difference was observed between the results of Ad-REIC and Ad-LacZ treatment (*P<0.05).

Figure 3. The detection of OVA-specific CTL induction using OVA tetramer assay
Tumor and spleen were harvested and immediately digested. Single cell suspensions were stained with OVA tetramer.
(a) TILs were collected 2 days after treatment. After gating on CD8 lymphocytes, OVA-specific T cells were analyzed by flow cytometry.
(b) Spleen cells were stimulated with OVA peptide for one week.
(c) The proportion of OVA-specific CTLs in the tumor and spleen are shown. The P value was calculated using the paired t-test.
Figure 4. The effector function of CTLs
(a) TILs and TDLNs were isolated from the treated mice on day 2 after the injection of Ad-REIC or Ad-LacZ injection. For intracellular staining, all cells were restimulated with PMA/ionomycin for 4 h before analysis. After stimulation, all samples were stained for anti-CD8 and intracellular IFN-γ.
(b) The mean cell populations of CD8+ and IFN-γ producing cells in response to 4h of stimulation with PMA/Ionomycin.
(c) The proportion of IFN-γ producing cells in TILs (left) and TDLNs (right).
* Student's unpaired t-test, P < 0.05, averaged from three separate experiments.

Figure 5. The phenotype and frequency of DC populations in TDLNs
(a) A flow cytometric analysis of DCs purified in TDLN of Ad-REIC or Ad-LacZ mice, and stained with mAbs for CD11c, MHC class II and CD86.
(b) Percentage of each population among CD19– CD11cint MHCII+ cells and among CD19– CD11chigh MHCII+ cells. The mean ± SD in three mice is shown.
(c) Histograms showing CD86 expression in migratory DCs (left) and resident DCs (right).

Figure 6. The antitumor effects in the Ad-REIC non-injection side
(a) The experimental schedule of the Ad-REIC treatment is shown. E.G7 cells were inoculated into the left and right back. 1.0 x 10⁹ pfu of Ad-REIC or Ad-LacZ were intoratumorally injected in only right side tumor.
(b) Non-injected TILs were isolated on post-treatment day 2. All cells were stained with anti-CD8 and OVA tetramer beads and were analyzed by flow cytometry. The overall frequency of the OVA tetramer+ T cells in the non-injection side tumor. The P value was calculated using the paired t-test.
(c) The tumor growth curves and a macroscopic view of E.G7 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed between Ad-REIC group and the control vector groups.

(d) The tumor growth curves of E.G7 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed in the directly treated tumor between Ad-REIC group and Ad-REIC plus anti-CD8 antibody added groups. †A significant difference was observed in the opposite (non-injected) tumor between Ad-REIC group and Ad-REIC plus anti-CD8 antibody added groups.

(e) The tumor growth curves of PSA-RM9 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed in the directly treated tumor between Ad-REIC group and the control vector groups. †A significant difference was observed in the opposite (non-injected) tumor between Ad-REIC group and the control vector groups.


Figure 1. The induction of apoptosis in E.G7 tumor cells after infection with Ad-REIC

(a)

(b)
Figure 2.
The antitumor effect of in situ Ad-REIC gene therapy

(a) E.G7 Tumor inoculation

Approximate tumor volume <50 - 100 mm³>

Ad-REIC or Ad-LacZ intratumoral injection (1.0 x 10⁹ pfu)

(b)

<table>
<thead>
<tr>
<th></th>
<th>PBS</th>
<th>LacZ</th>
<th>REIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>kDa</td>
<td>100</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>37</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E.G7 tumor inoculation

Approximate tumor volume <50 - 100 mm³

Ad-REIC or Ad-LacZ intratumoral injection (1.0 x 10⁹ pfu)

Days after treatment

(c)

- **REIC**
- **LacZ**

<table>
<thead>
<tr>
<th>day0</th>
<th>day2</th>
<th>day4</th>
<th>day6</th>
<th>day8</th>
<th>day10</th>
<th>day12</th>
<th>day14</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>20</td>
<td>40</td>
<td>60</td>
<td>80</td>
<td>100</td>
<td>120</td>
<td>140</td>
</tr>
</tbody>
</table>

Approximate tumor volume (mm³)

Days after treatment

- ↑
- ↑
Figure 3.
The detection of OVA-specific CTL induction using by OVA tetramer assay

(a) LacZ

(b) REIC

(c) Spleen

TIL

Spleen

OVA tetramer/CD8(%)
Figure 4. The effector function of CTLs

(a) LacZ

(b) REIC

(c) IFN+ cell in TIL

IFN+ cell in TDLN

IFN+/(CD8 (%) 3

0 1 2 3

LacZ REIC

LacZ REIC

IFN+/(CD8 (%) 3

0 1 2 3

LacZ REIC
Figure 5. The phenotype and frequency of DC populations in TDLNs

(a) LacZ REIC

Number of DC (cells)

(b) CD103+ mDC (%) CD8+ rDC (%)

(c) mDC rDC

mean fluorescence intensity (MFI)
Figure 6. The antitumor effects in the Ad-REIC non-injection side

(a) E.G7 Tumor inoculation at dual side
Approximate tumor volume <50 - 100 mm³>
Non injection TILs were harvested 48hr after second injection
Ad-REIC or Ad-LacZ intratumoral injection only at right side

(b) OVA-tetramer
CD8
0.41
10.8
LacZ
REIC

OVA tetramer/CD8(%)
Figure 6. The antitumor effects in the Ad-REIC non-injection side

(c) indirect anti-tumor effect

(d)
(e)  

![Graph showing tumor volume over days after treatment](image)

- **Control**
- **Ad-LacZ injection**
- **Ad-LacZ non-injection side**
- **Ad-REIC injection**
- **Ad-REIC non-injection side**

**Days after treatment**

- **Day 0**
- **Day 2**
- **Day 4**
- **Day 6**
- **Day 8**

**Tumor volume (mm³)**

* * p < 0.05 compared between Ad-REIC injection and Ad-LacZ injection
† † p < 0.05 compared between Ad-REIC non-injection and Ad-LacZ non-injection side